# To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

> **NCT03743259** · PHASE2 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- Breast Diseases

## Interventions

- **DRUG:** LuminoMark inj. 0.1mL
- **DRUG:** LuminoMark inj. 0.2mL
- **DRUG:** Charcotrace Inj.

## Key facts

- **NCT ID:** NCT03743259
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-29
- **Primary completion:** 2019-01-11
- **Final completion:** 2019-04-22
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743259, "To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03743259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*